Since a long-term, randomized trial for romiplostim is impractical, the proposed next step is to conduct large-scale, retrospective epidemiological studies. This approach would compare outcomes in matched populations of patients who did and did not receive the drug, representing a pragmatic shift in research strategy.

With effective obesity drugs widely available, patients in trials quickly realize they are on placebo and drop out, compromising data integrity. This is pushing the industry toward using existing drugs as the control arm, making trials more complex and expensive but yielding more realistic, comparative data on efficacy and tolerability.

Trials adding an investigational drug to steroids for initial chronic GVHD treatment consistently fail because many patients respond to steroids alone in the short term. This early efficacy masks the new drug's potential benefit, leading to failed studies (e.g., with mycophenolate, ibrutinib, belumosudil) and a push towards new trial designs.

The RECITE trial proved romiplostim effectively maintains platelet counts, allowing patients to receive their full, intended chemotherapy dose (relative dose intensity). However, the critical link between maintaining this dose and actually improving progression-free or overall survival has not yet been established.

Clinicians identify outdated control arms—like single-agent chemotherapy without newer targeted agents—as a major deterrent for patient trial participation. Patients are unwilling to be randomized to a therapy that doesn't reflect the current, more effective standard of care. This pressure is forcing sponsors and the FDA to design trials with more realistic comparator arms.

The expected rapid approval of the highly effective RAS inhibitor daraxonrasib poses a dual crisis. It creates an urgent need for equitable patient access globally while simultaneously making future randomized trials against standard chemotherapy nearly impossible to recruit, as patients will be unwilling to join the control arm.

The FDA's demand for a randomized controlled trial for a Huntington's drug is ethically compromised. Patients in the placebo group would likely progress beyond the specific disease stage (TFC 9-13) required for treatment, making them permanently ineligible for the drug if it's eventually approved.

Despite lacking specific FDA approval for chemotherapy-induced thrombocytopenia (CIT), romiplostim is widely used and reimbursed. This is because the influential National Comprehensive Cancer Network (NCCN) endorsed its use based on earlier Phase II data, demonstrating how clinical guidelines can establish standard of care.

The approval of effective therapies like nirogacestat creates an ethical dilemma. For patients with progressing tumors, continuing to use a placebo arm in clinical trials may no longer be appropriate, challenging future research design for this rare disease.